251 related items for PubMed ID: 23283289
21. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
[Abstract] [Full Text] [Related]
22. [The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases].
Peyre M, Laroche C, Etchecopar C, Brosset P.
Arch Pediatr; 2013 Jul; 20(7):748-53. PubMed ID: 23693156
[Abstract] [Full Text] [Related]
23. Management of acute and refractory Kawasaki disease.
Tacke CE, Burgner D, Kuipers IM, Kuijpers TW.
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[Abstract] [Full Text] [Related]
24. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[Abstract] [Full Text] [Related]
25. Recent developments and controversies in Kawasaki disease.
Guzman-Cottrill JA, Shulman ST.
Minerva Pediatr; 2004 Feb; 56(1):51-61. PubMed ID: 15249914
[Abstract] [Full Text] [Related]
26. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.
De Rosa G, Pardeo M, Rigante D.
Eur Rev Med Pharmacol Sci; 2007 Feb; 11(5):301-8. PubMed ID: 18074939
[Abstract] [Full Text] [Related]
27. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
28. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
29. Kawasaki disease: Medical therapies.
Newburger JW.
Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
[Abstract] [Full Text] [Related]
30. [Kawasaki disease: what you need to know].
Bajolle F, Laux D.
Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
[Abstract] [Full Text] [Related]
31. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
[Abstract] [Full Text] [Related]
32. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
Davies S, Gold-von Simson G.
Pediatr Cardiol; 2013 Oct 03; 34(7):1756. PubMed ID: 23771701
[No Abstract] [Full Text] [Related]
33. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
Pediatrics; 1995 Dec 03; 96(6):1057-61. PubMed ID: 7491221
[Abstract] [Full Text] [Related]
34. Kawasaki disease.
Scuccimarri R.
Pediatr Clin North Am; 2012 Apr 03; 59(2):425-45. PubMed ID: 22560578
[Abstract] [Full Text] [Related]
35. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
Nihon Rinsho; 2008 Feb 03; 66(2):338-42. PubMed ID: 18265457
[Abstract] [Full Text] [Related]
36. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K, Sangtawesin C, Khongphatthanayopthin A, Panamonta M, Sopontammarak S, Sittiwangkul R, Pongpanich B.
Asian Pac J Allergy Immunol; 2006 Mar 03; 24(1):27-32. PubMed ID: 16913186
[Abstract] [Full Text] [Related]
37. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
[Abstract] [Full Text] [Related]
38. Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms.
Selamet Tierney ES, Runeckles K, Tremoulet AH, Dahdah N, Portman MA, Mackie AS, Harahsheh AS, Lang SM, Choueiter NF, Li JS, Manlhiot C, Low T, Mathew M, Friedman KG, Raghuveer G, Norozi K, Szmuszkovicz JR, McCrindle BW, International Kawasaki Disease Registry.
J Pediatr; 2022 Jan 28; 240():164-170.e1. PubMed ID: 34474088
[Abstract] [Full Text] [Related]
39. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ, Kim KH, Chun JK, Kim DS.
Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
[Abstract] [Full Text] [Related]
40. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
Pediatr Int; 2001 Jun 31; 43(3):211-7. PubMed ID: 11380911
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
